explore -WSS

explore

author：leisure time 2025-10-02 13:37:42 - browse：77

AstraZeneca said Friday it will buy up a group of early-stage gene therapies from Pfizer, bucking a trend of drugmakers axing programs and exiting a field that had once captured the imagination — and checkbooks — of many pharmaceutical executives.

AstraZeneca will pay Pfizer up to $1 billion plus royalties for the portfolio of treatments, none of which has entered clinical trials yet. The companies did not say how much it is paying upfront.

The moves come six months after Pfizer said it would stop much of its work on early-stage gene therapy programs, in which researchers try to deliver replacement genes encased in small, non-pathogenic bugs called adeno-associated viruses, or AAVs. Instead, it would focus on newer technologies, such as gene editing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Advances in CAR

WSS

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

How generative AI is inspiring dreams of a health data revolution

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

NIH nominee Bertagnolli will get October confirmation hearing

Beware reading your test results before your doctor does

Undocumented workers face uncertainty as immigration law takes effect in Florida

Wikipedia

explore

explore

Malaria cases in Florida and Texas: Here’s what you need to know

A rare thyroid diagnosis led to unexpected, all

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Amazon on where the company's health care bets are headed next

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Humana sues Biden admin over Medicare Advantage audit rule

ChatGPT in medicine: STAT answers readers' burning questions

Medicaid rebukes states for mistakenly disenrolling children

Malaria cases in Florida and Texas: Here’s what you need to know

Dexcom's push to bring CGM to type 2 diabetes patients

knowledge

Trump surgeon general acknowledges mistakes during Covid

Snackable artificial intelligence, expert AI, and the pharma industry

A letter from the executive editor: The 2023 STATUS List

The (many) problems with a new study criticizing cancer screening

Crowdfunding for unproven stem cell procedures spreads misinformation

Grandmother of French teen shot dead by police officer pleads with rioters to stop the violence

entertainment

leisure time

Wikipedia

hotspot